These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 498415)

  • 1. Comparative study in mice of the toxicity, pharmacology, and therapeutic activity of daunorubicin-DNA and doxorubicin-DNA complexes.
    Deprez-De Campeneere D; Baurain R; Huybrechts M; Trouet A
    Cancer Chemother Pharmacol; 1979; 2(1):25-30. PubMed ID: 498415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and adriamycin.
    Deprez-de Campeneere D; Baurain R; Trouet A
    Cancer Treat Rep; 1979 May; 63(5):861-7. PubMed ID: 455327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA--anthracycline complexes. I. Toxicity in mice and chemotherapeutic activity against L1210 leukemia of daunorubicin--DNA and adriamycin--DNA.
    Deprez-de Campeneere D; Trouet A
    Eur J Cancer (1965); 1980 Aug; 16(8):981-6. PubMed ID: 7439227
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacological and therapeutic efficacy of rubidazone in mice. Comparison with daunomycin and adriamycin.
    Ohnuma T; Elias F; Holland JF; Henderson E
    Eur J Cancer (1965); 1979 Mar; 15(3):363-71. PubMed ID: 446517
    [No Abstract]   [Full Text] [Related]  

  • 5. Interaction of aclarubicin with DNA as compared with daunorubicin and doxorubicin.
    Ando S; Sasada M; Uchino H; Kagawa D; Ueda T; Nakamura T
    Nihon Gan Chiryo Gakkai Shi; 1986 Dec; 21(10):2343-55. PubMed ID: 3471823
    [No Abstract]   [Full Text] [Related]  

  • 6. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
    Woodman RJ; Cysyk RL; Kline I; Gang M; Venditti JM
    Cancer Chemother Rep; 1975; 59(4):689-95. PubMed ID: 1175163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daunorubicin-DNA and doxorubicin-DNA. A review of experimental and clinical data.
    Trouet A; Deprez-De Campeneere D
    Cancer Chemother Pharmacol; 1979; 2(1):77-9. PubMed ID: 498424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter: DNA complexes of daunorubicin (NSC-8215) and adriamycin (NSC-123127).
    Trouet A; de Duve C
    Cancer Chemother Rep; 1975; 59(2 Pt 1):260. PubMed ID: 1149004
    [No Abstract]   [Full Text] [Related]  

  • 9. Antileukemic activity of 4-demethoxydaunorubicin in mice.
    Casazza AM; Pratesi G; Giuliani F; Di Marco A
    Tumori; 1980 Oct; 66(5):549-64. PubMed ID: 6936969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy through lysosomes with a DNA-daunorubicin complex.
    Trouet A; Deprez-de Campeneere D; De Duve C
    Nat New Biol; 1972 Sep; 239(91):110-2. PubMed ID: 4507516
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative toxicity of detorubicin and doxorubicin, free and DNA-bound, for hemopoietic stem cells.
    Huybrechts M; Trouet A
    Cancer Chemother Pharmacol; 1980; 5(2):79-82. PubMed ID: 7471318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo study of cross resistance between daunorubicin and daunorubicin-DNA complex in Ehrlich ascites tumor.
    Skovsgaard T
    Cancer Chemother Pharmacol; 1979; 2(1):43-7. PubMed ID: 498419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake of free and DNA-bound daunorubicin and doxorubicin into human leukemic cells.
    Paul C; Peterson C; Gahrton G; Lockner D
    Cancer Chemother Pharmacol; 1979; 2(1):49-52. PubMed ID: 498420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Some determinants of the therapeutic efficacy of actinomycin D (NSC-3053), adriamycin (NSC-123127), and daunorubicin (NSC-83142).
    Schwartz HS
    Cancer Chemother Rep; 1974; 58(1):55-62. PubMed ID: 4521481
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin.
    Giuliani F; Casazza AM; Di Marco A; Savi G
    Cancer Treat Rep; 1981; 65(3-4):267-76. PubMed ID: 6263470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of activity of daunorubicin, adriamycin and stereoisomers following the introduction or removal of hydroxyl groups in the amino sugar moiety.
    Di Marco A; Casazza AM; Dasdia T; Necco A; Pratesi G; Rivolta P; Velcich A; Zaccara A; Zunino F
    Chem Biol Interact; 1977 Dec; 19(3):291-302. PubMed ID: 597963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased cardiac toxicity of adriamycin and daunorubicin when bound to DNA.
    Langslet A; Oye I; Lie SO
    Acta Pharmacol Toxicol (Copenh); 1974 Nov; 35(5):379-85. PubMed ID: 4479715
    [No Abstract]   [Full Text] [Related]  

  • 19. Daunomycin- and adriamycin-N-(2-hydroxypropyl)methacrylamide copolymer conjugates; toxicity reduction by improved drug-delivery.
    Seymour LW; Duncan R; Kopecková P; Kopecek J
    Cancer Treat Rev; 1987 Dec; 14(3-4):319-27. PubMed ID: 3326668
    [No Abstract]   [Full Text] [Related]  

  • 20. Amino acid and dipeptide derivatives of daunorubicin. 2. Cellular pharmacology and antitumor activity on L1210 leukemic cells in vitro and in vivo.
    Baurain R; Masquelier M; Deprez-De Campeneere D; Trouet A
    J Med Chem; 1980 Nov; 23(11):1171-4. PubMed ID: 7452666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.